A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

1,707

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

July 26, 2019

Study Completion Date

December 17, 2019

Conditions
Meningitis, Meningococcal
Interventions
BIOLOGICAL

MenACWY liquid

At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY\_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY\_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.

BIOLOGICAL

MenACWY

At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY\_1) or in phase 2 of the study (subjects randomized to study arm ACWY\_2), administered by intramuscular injection in the deltoid of the non-dominant arm.

Trial Locations (49)

7530

GSK Investigational Site, Bellville

10117

GSK Investigational Site, Tallinn

11313

GSK Investigational Site, Tallinn

19300

GSK Investigational Site, Rosiers-d'Égletons

26040

GSK Investigational Site, Eskişehir

28050

GSK Investigational Site, Madrid

28100

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

34000

GSK Investigational Site, Durango

35340

GSK Investigational Site, Izmir

37044

GSK Investigational Site, Tours

41014

GSK Investigational Site, Seville

44277

GSK Investigational Site, Nantes

46011

GSK Investigational Site, Valencia

46022

GSK Investigational Site, Valencia

46200

GSK Investigational Site, Valencia

46930

GSK Investigational Site, Quart de Poblet, Valencia

49000

GSK Investigational Site, Angers

50106

GSK Investigational Site, Tartu

90220

GSK Investigational Site, Oulu

97070

GSK Investigational Site, Mérida

115478

GSK Investigational Site, Moscow

150051

GSK Investigational Site, Yaroslavl

183038

GSK Investigational Site, Murmansk

188300

GSK Investigational Site, Gatchina

191025

GSK Investigational Site, Saint Petersburg

196240

GSK Investigational Site, Saint Petersburg

197022

GSK Investigational Site, Saint Petersburg

197089

GSK Investigational Site, Saint Petersburg

620028

GSK Investigational Site, Yekaterinburg

40420-000

GSK Investigational Site, Salvador

59025-050

GSK Investigational Site, Natal

22271-100

GSK Investigational Site, Rio de Janeiro

01228-200

GSK Investigational Site, São Paulo

04266-010

GSK Investigational Site, São Paulo

Unknown

GSK Investigational Site, Tallinn

GSK Investigational Site, Barcelona

GSK Investigational Site, Valencia

02230

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

06300

GSK Investigational Site, Nice

634 050

GSK Investigational Site, Tomsk

0152

GSK Investigational Site, Pretoria

08025

GSK Investigational Site, Barcelona

08540

GSK Investigational Site, Centelles (Barcelona)

08907

GSK Investigational Site, L'Hospitalet de Llobregat

08430

GSK Investigational Site, La Roca Del Valles (Barcelona)

08500

GSK Investigational Site, Vic/ Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03433482 - A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age | Biotech Hunter | Biotech Hunter